O2-Supplying Nanozymes Alleviate Hypoxia and Deplete Lactate to Eliminate Tumors and Activate Antitumor Immunity
Source abstract
Abstract
Direct hypoxia alleviation and lactate depletion in the tumor microenvironment (TME) are promising for effective cancer therapy but still very challenging. To address this challenge, the current research directly reshapes the TME for inhibiting tumor growth and activating the antitumor immunity using a drug-free nanozyme. Herein, the acid-sensitive nanozymes were constructed based on peroxidized layered double hydroxide nanoparticles for O2 self-supply and self-boosted lactate depletion. The coloading of partially cross-linked catalase and lactate oxidase enabled the acid-sensitive nanozymes to promote three reactions, that is, (1) H2O2 generation from MgO2 hydrolysis (30% at pH 7.4 vs 63% at pH 6.0 in 8 h); (2) O2 generation from H2O2 (12% at pH 7.4 vs 21% at pH 6.0 in 2 h); and (3) lactate depletion by in situ generated O2 (50% under hypoxia vs 75% under normoxia in 24 h in vitro) in parallel or tandem. These promoted reactions together efficiently induced colon cancer cell apoptosis under the hypoxic conditions, significantly inhibited tumor growth (>95%), and suppressed distant tumor growth upon seven administrations in every 3 days and moreover transformed the immunosuppressive tumor into “hot” one in the colon tumor-bearing mouse model. This is the first example for a nanozyme that supplies sufficient O2 for hypoxia relief and lactate depletion, thus providing a new insight into drug-free nanomaterial-mediated TME-targeted cancer therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer, Hypoxia, and Metabolism · Immune cells in cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD4072Australia
Centre for Biomedical Technologies, Queensland University of Technology, Brisbane, QLD4059, Australia
State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai201203, China
Funding
Australian Research Council · Queensland University of Technology
References (48)
Show source-provided references
1. 10.1016/j.mattod.2015.11.02510.1016/j.mattod.2015.11.025 ↗
2. 10.1021/acs.accounts.8b0021410.1021/acs.accounts.8b00214 ↗
3. 10.1007/s40820-020-00549-410.1007/s40820-020-00549-4 ↗
4. 10.1002/smll.20210013010.1002/smll.202100130 ↗
5. 10.1002/adma.20180332210.1002/adma.201803322 ↗
6. 10.1002/adma.20200208510.1002/adma.202002085 ↗
7. 10.1038/nrc147810.1038/nrc1478 ↗
8. 10.1038/nature1349010.1038/nature13490 ↗
9. 10.1038/s41590-018-0258-010.1038/s41590-018-0258-0 ↗
10. 10.3389/fimmu.2016.0005210.3389/fimmu.2016.00052 ↗
11. 10.1021/acsnano.7b0485510.1021/acsnano.7b04855 ↗
12. 10.1080/2162402x.2015.101477410.1080/2162402x.2015.1014774 ↗
13. 10.1002/smll.20190374610.1002/smll.201903746 ↗
14. 10.1016/j.biomaterials.2018.08.01110.1016/j.biomaterials.2018.08.011 ↗
15. 10.1016/j.biomaterials.2020.11975510.1016/j.biomaterials.2020.119755 ↗
16. 10.1016/j.biomaterials.2021.12098710.1016/j.biomaterials.2021.120987 ↗
17. 10.1038/s41467-020-15591-410.1038/s41467-020-15591-4 ↗
18. 10.1002/advs.20210024110.1002/advs.202100241 ↗
19. 10.1002/adma.20190401110.1002/adma.201904011 ↗
20. 10.1016/j.nantod.2020.10092310.1016/j.nantod.2020.100923 ↗
21. 10.1002/advs.20200027210.1002/advs.202000272 ↗
22. 10.1039/c5tb00248f10.1039/c5tb00248f ↗
23. 10.1021/jp002925710.1021/jp0029257 ↗
24. 10.1002/sstr.20200011210.1002/sstr.202000112 ↗
25. 10.1016/j.biomaterials.2018.05.05510.1016/j.biomaterials.2018.05.055 ↗
26. 10.1016/j.jcis.2019.11.12210.1016/j.jcis.2019.11.122 ↗
27. 10.1016/j.jhazmat.2020.12287710.1016/j.jhazmat.2020.122877 ↗
28. 10.1021/acsomega.0c0552010.1021/acsomega.0c05520 ↗
29. 10.1016/j.cmet.2005.05.00110.1016/j.cmet.2005.05.001 ↗
30. 10.1038/nrc246810.1038/nrc2468 ↗
31. 10.1002/anie.20200146910.1002/anie.202001469 ↗
32. 10.1038/sj.cdd.440125210.1038/sj.cdd.4401252 ↗
33. 10.1128/mcb.22.1.94-104.200210.1128/mcb.22.1.94-104.2002 ↗
34. 10.1136/jcp.2003.01503210.1136/jcp.2003.015032 ↗
35. 10.1046/j.1471-4159.2000.0750683.x10.1046/j.1471-4159.2000.0750683.x ↗
36. 10.1186/1476-4598-2-2310.1186/1476-4598-2-23 ↗
37. 10.1002/adma.20170037310.1002/adma.201700373 ↗
38. 10.1021/acsami.9b1174610.1021/acsami.9b11746 ↗
39. 10.1002/adfm.20210326210.1002/adfm.202103262 ↗
40. 10.1126/science.110481910.1126/science.1104819 ↗
41. 10.1038/s41467-018-04318-110.1038/s41467-018-04318-1 ↗
42. 10.18632/oncotarget.553810.18632/oncotarget.5538 ↗
43. 10.1038/ni.270310.1038/ni.2703 ↗
44. 10.1002/adma.20180830310.1002/adma.201808303 ↗
45. 10.1080/15384101.2018.144430510.1080/15384101.2018.1444305 ↗
46. 10.1021/acs.bioconjchem.9b0061810.1021/acs.bioconjchem.9b00618 ↗
47. 10.1016/s0003-2670(00)86374-610.1016/s0003-2670(00)86374-6 ↗
48. 10.1002/adhm.20190170610.1002/adhm.201901706 ↗